https://doi.org/10.4081/itjm.2023.1660

Rare but possible: clopidogrel-induced pancytopenia

Vol. 17 No. 3 (2023)
Published: 10 October 2023
Clopidogrel, neutropenia, myocardial infarction, adverse drug reaction
Abstract Views: 807
PDF: 310
HTML: 100
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Pietro Bocchi
pietro.bocchi@ausl.pr.it
https://orcid.org/0009-0008-8939-1189
Department of Internal Medicine, Vaio Hospital, Fidenza (PR), Italy.
Pasquale Gianluca Giuri
Department of Internal Medicine, Santa Maria Hospital, Borgo Val di Taro (PR), Italy.
Achiropita Bovino
Department of Internal Medicine, Vaio Hospital, Fidenza (PR), Italy.
Alessia Casola
Department of Internal Medicine, Vaio Hospital, Fidenza (PR), Italy.
Simona Detrenis
Department of Internal Medicine, Santa Maria Hospital, Borgo Val di Taro (PR), Italy.
Marcello Bertorelli
Department of Clinical Cardiology, Cardiologic Rehabilitation and High Care Ward, Santa Maria Hospital, Borgo Val di Taro (PR), Italy.
Michele Meschi
Department of Internal Medicine, Vaio Hospital, Fidenza (PR), Italy.
Giancarlo Mangè
Department of Internal Medicine, Vaio Hospital, Fidenza (PR), Italy.

We present the case of an 84-year-old female patient admitted to the Internal Medicine Ward for atypical chest pain and laboratory findings of severe pancytopenia. Past medical history was remarkable for an episode of myocardial infarction approximately 4 weeks prior to the current hospitalization which had required angioplasty + drug-eluting stent and dual antiplatelet therapy with acetylsalicylic acid and clopidogrel. Some rare cases of clopidogrel-induced pancytopenia are described in scientific literature, therefore, after excluding infectious, vitamin deficiencies, and autoimmune causes, we modified the antiplatelet therapy by replacing clopidogrel with ticagrelor, obtaining complete leukocyte recovery within a few days. Since clopidogrel is an antiplatelet drug still used in clinical cardiological practice, the knowledge of this rare side effect may lead the clinician to suspect hematological toxicity which, if recognized promptly, may suggest modification of antiplatelet therapy and limit any possible infectious complications for the care of the patient.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Boxer LA. How to approach neutropenia. Hematology Am Soc Hematol Educ Program 2012;2012:174-82. DOI: https://doi.org/10.1182/asheducation.V2012.1.174.3798251
Almsherqi ZA, McLachlan CS, Sharef SM. Non-bleeding side effects of clopidogrel: have large multi-center clinical trials underestimated their incidence? Int J Cardiol 2007;117:415-7. DOI: https://doi.org/10.1016/j.ijcard.2006.05.058
Gent M, Beaumont D, Blanchard J, et al. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39. DOI: https://doi.org/10.1016/S0140-6736(96)09457-3
Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. DOI: https://doi.org/10.1056/NEJMoa010746
McCarthy MW, Kockler DR. Clopidogrel-associated leukopenia. Ann Pharmacother 2003;37:216-9. DOI: https://doi.org/10.1345/aph.1C233
Schäfer A, Eigenthaler M, Bauersachs J. Severe neutropenia under clopidogrel treatment three weeks after coronary stenting. Thromb Haemost 2007;97:317-8. DOI: https://doi.org/10.1160/TH06-10-0608
Pan Y, Liu B, Liu J, et al. Clopidogrel-induced neutropenia in an 80-year-old patient with chronic kidney disease who underwent percutaneous coronary intervention: a case report and literature review. BMC Cardiovasc Disord 2022;22. DOI: https://doi.org/10.1186/s12872-022-02490-3
Kabil MF, Abo Dena AS, El-Sherbiny IM. Ticagrelor. Profiles Drug Subst Excip Relat Methodol 2022;47:91-111. DOI: https://doi.org/10.1016/bs.podrm.2021.10.003
Krakowiak A, Kuleta J, Plech I, et al Ticagrelor-Related Severe Dyspnoea: Mechanisms, Characteristic Features, Differential Diagnosis and Treatment. Clin Med Insights Case Rep 2020;13. DOI: https://doi.org/10.1177/1179547620956634
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007;357:2001-15. DOI: https://doi.org/10.1056/NEJMoa0706482

How to Cite

Bocchi, P., Giuri, P. G., Bovino, A., Casola, A., Detrenis, S., Bertorelli, M., Meschi, M., & Mangè, G. (2023). Rare but possible: clopidogrel-induced pancytopenia. Italian Journal of Medicine, 17(3). https://doi.org/10.4081/itjm.2023.1660
Copyright (c) 2023 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.


List of Cited By :

Crossref logo